AstraZeneca PLC is 13.5x more valuable than Royalty Pharma plc by market capitalization ($286.27 B vs $21.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RPRX | AZN |
|---|---|---|
| Market cap | $21.16 B | $286.27 B |
| US-listed rank | #600 | #45 |
| Revenue (latest FY) | $2.38B | - |
| Net income (latest FY) | $770.95M | - |
| Net margin | 32.4% | - |
| P/E (trailing FY) | 27.4 | - |
| SEC filings | 588 | 1,004 |
AstraZeneca PLC is 13.5x more valuable than Royalty Pharma plc by market capitalization ($286.27 B vs $21.16 B).
Full pages: Royalty Pharma plc and AstraZeneca PLC, or browse the full rankings.